← Oncology Approval Tracker

FDA DECISION ·

Keytruda

pembrolizumab · Merck

FDA approvalNew or expanded indicationEndometrial cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Single-agent treatment of advanced endometrial carcinoma identified as MSI-high or mismatch-repair-deficient by an FDA-approved test, after progression on prior systemic treatment in any setting when curative surgery or radiation is unsuitable.

LAMPGEN ANALYSIS

Why it matters

This defines an endometrial-specific monotherapy pathway based on MSI or mismatch repair status.

What research teams should watch

Capture the biomarker report, progression on prior therapy, and the decision about local curative treatment.

PRIMARY RECORDS

Sources